



## Índice de intervenções por tema

### B. IMAGING -> 03. IMAGING -> 03.1 ECHOCARDIOGRAPHY

- PO 121 PROGNOSTIC SIGNIFICANCE OF PEAK ATRIAL LONGITUDINAL STRAIN IN PATIENTS WITH FUNCTIONAL MITRAL REGURGITATION
- PO 122 IDENTIFICATION OF HIGH-RISK PATIENTS WITH NON-ST SEGMENT ELEVATION ACUTE CORONARY SYNDROMES USING STRAIN ANALYSIS
- PO 123 QUANTITATIVE LONGITUDINAL PEAK SYSTOLIC STRAIN IN THE DETECTION OF LEFT VENTRICULAR WALL MOTION ABNORMALITIES: AN ANALYSIS OF OUR DAILY ECHOCARDIOGRAPHIC PRACTICE
- PO 124 PROGNOSTIC VALUE OF EXERCISE STRESS ECHOCARDIOGRAPHY IN PATIENTS WITH KNOWN CORONARY ARTERY DISEASE
- PO 125 MITRAL REGURGITATION ON LOW-FLOW LOW-GRADIENT SEVERE AORTIC STENOSIS AND PRESERVED EJECTION FRACTION
- PO 221 CAN WE COUNT ON ECHOCARDIOGRAPHY TO IDENTIFY DIFFERENT TYPES OF CARDIAC AMYLOIDOSIS?
- PO 222 AN ECHOCARDIOGRAPHIC INSIGHT ON POST-COVID-19 SYMPTOMS.
- PO 223 CLINICAL AND ECHOCARDIOGRAPHIC FEATURES OF PLATYPNEA-ORTHODEOXIA SYNDROME: A SINGLE-CENTRE EXPERIENCE
- PO 224 PROGNOSTIC VALUE OF MITRAL ANNULAR PLANE SYSTOLIC EXCURSION IN PATIENTS WITH ACUTE CORONARY SYNDROME AND PRESERVED EJECTION FRACTION.
- PO 225 LONG TERM LEFT VENTRICULAR IMPAIRMENT AFTER SARS-COV2 INFECTION
- CO 131 REGIONAL IMPAIRMENT OF LEFT VENTRICULAR LONGITUDINAL STRAIN IN AORTIC REGURGITATION - HAVE WE FOUND THE MISSING PIECE?
- CO 133 RELATIVE APICAL SPARING IN SEVERE AORTIC STENOSIS: DOES IT MEAN CONCOMITANT AMYLOID CARDIOMYOPATHY?
- CO 134 LEFT ATRIAL STRAIN ANALYSIS IN PATIENTS WITH SEVERE RHEUMATIC MITRAL STENOSIS SUBMITTED TO MITRAL BALLOON VALVULOPLASTY
- CO 135 PROGNOSTIC VALUE OF GLOBAL LONGITUDINAL STRAIN IN PATIENTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY

### B. IMAGING -> 03. IMAGING -> 03.2 COMPUTED TOMOGRAPHY

- PO 2 ASSOCIATION OF EPICARDIAL FAT AND CORONARY ARTERY CALCIUM SCORE IN PATIENTS WITH ATRIAL FIBRILLATION
- PO 3 GENDER-SPECIFIC DIFFERENCES IN OBSTRUCTIVE CORONARY ARTERY DISEASE BY CORONARY CT ANGIOGRAPHY
- PO 4 LOW CORONARY CALCIUM SCORE IN PATIENTS WITH OBSTRUCTIVE CORONARY DISEASE
- PO 5 ARTIFICIAL INTELLIGENCE-ENABLED COMPREHENSIVE CORONARY PHENOTYPING IN PATIENTS WITH SUSPECTED CAD
- CO 51 USE OF CORONARY CALCIUM SCORE TO REFINE THE CARDIOVASCULAR RISK CLASSIFICATION OF THE NEW SCORE-2 AND SCORE-2 OP ALGORITHMS IN PATIENTS UNDERGOING CORONARY CT ANGIOGRAPHY
- CO 52 INDEXING CALCIUM SCORE OF THE AORTIC VALVE TO THE ANNULUS AREA IMPROVES THE GRADING OF AORTIC STENOSIS SEVERITY IN PATIENTS WITHIN THE "GREY ZONE" OF AORTIC VALVE CALCIFICATION

- CO 93 IMPLICATIONS OF THE NORTH AMERICAN 2021 CHEST PAIN GUIDELINES IN THE DIAGNOSTIC APPROACH TO PATIENTS WITH STABLE CHEST PAIN AND LOW PRETEST PROBABILITY OF OBSTRUCTIVE CORONARY ARTERY DISEASE

## **B. IMAGING -> 03. IMAGING -> 03.3 CARDIAC MAGNETIC RESONANCE**

- PO 201 MYOCARDIAL INFARCTION IN THE ABSENCE OF OBSTRUCTIVE CORONARY ARTERY DISEASE - CARDIAC MAGNETIC RESONANCE USE IN IDENTIFYING THE UNDERLYING CAUSES
- PO 202 QUANTITATIVE COMPARISON BETWEEN 2D VERSUS 3D LATE GADOLINIUM ENHANCEMENT FOR MYOCARDIAL SCAR CHARACTERIZATION - POSSIBLE IMPLICATION FOR INTERVENTION GUIDANCE AND ARRHYTHMOGENIC RISK ASSESSMENT
- PO 203 LEFT VENTRICULAR MECHANICS IN PATIENTS WITH LEFT BUNDLE BRANCH BLOCK ASSESSED BY CARDIAC MAGNETIC RESONANCE - INFLUENCE OF ETIOLOGY AND PRESENCE OF FIBROSIS
- PO 204 VENTRICULAR ARRHYTHMIA IN PATIENTS WITH NORMAL ECHOCARDIOGRAPHY - CAN CARDIOVASCULAR MAGNETIC RESONANCE ENHANCE THE DIAGNOSIS OF STRUCTURAL HEART DISEASE?
- CO 53 LATE GADOLINIUM ENHANCEMENT PATTERNS IN SEVERE SYMPTOMATIC HIGH-GRADIENT AORTIC STENOSIS
- CO 55 LEFT VENTRICULAR REMODELING IN AORTIC STENOSIS PATIENTS REFERRED FOR SURGICAL AORTIC VALVE REPLACEMENT
- CO 132 A CMR MYOCARDIAL STRAIN PATTERNS ANALYSIS IN LEFT BUNDLE BRANCH BLOCK

## **B. IMAGING -> 03. IMAGING -> 03.4 NUCLEAR IMAGING**

- PO 1 CARDIAC FAT AND MICROCALCIFICATION AS SURROGATE MARKERS OF CORONARY ATHEROGENESIS
- PO 205 SEEING BEYOND PERFUSION - IS THERE A ROLE FOR OTHER HIGH-RISK ISCHEMIA MARKERS IN PATIENTS WITH NORMAL PERFUSION ON SPECT MYOCARDIAL PERFUSION IMAGING?
- CO 54 99MTC-DPD SCINTIGRAPHY IN THE DIAGNOSIS AND PROGNOSIS OF TRANSTHYRETIN V30M CARDIAC AMYLOIDOSIS

## **C. ARRHYTHMIAS AND DEVICE THERAPY -> 04. ARRHYTHMIAS, GENERAL -> 04.2 ARRHYTHMIAS, GENERAL - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

- PO 92 LONG-TERM PROGNOSIS IN PATIENTS WITH ATRIOVENTRICULAR BLOCK IN ACUTE CORONARY SYNDROME
- CO 108 PREVALENCE AND IMPACT OF TACHYARRHYTHMIAS IN PATIENTS ADMITTED WITH COVID-19 PNEUMONIA

## **C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.1 ATRIAL FIBRILLATION - PATHOPHYSIOLOGY AND MECHANISMS**

- PO 10 AUTONOMIC DYSFUNCTION IS DIVERSE IN REFLEX SYNCOPE AND ATRIAL FIBRILLATION
- CO 107 HIGHER CORONARY CALCIUM SCORE IS ASSOCIATED WITH INCREASED RISK OF ATRIAL FIBRILLATION RECURRENCE

## **C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.2 ATRIAL FIBRILLATION - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

- PO 6 BENEFIT OF SLEEP STUDY IN ALL PATIENTS WITH ATRIAL FIBRILLATION AND BMI > 28,0 KG/M2 BEFORE CATHETER ABLATION.
- PO 7 ROLE OF EPICARDIAL ADIPOSE TISSUE VOLUME AS PREDICTOR OF ATRIAL FIBRILLATION RECURRENCE
- PO 9 X-RAY AF: RESULTADOS PRINCIPAIS DO REGISTO DE FIBRILHAÇÃO AURICULAR EM PORTUGAL CONTINENTAL

## **C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.3 ATRIAL FIBRILLATION - DIAGNOSTIC METHODS**

- PO 213 SCREENING STRATEGIES FOR ATRIAL FIBRILLATION IN THE ELDERLY POPULATION: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

**C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.4 ATRIAL FIBRILLATION - TREATMENT**

- PO 8 EVALUATING THE VALUE OF THE TIMING OF RECURRENCE DURING BLANKING PERIOD AFTER ATRIAL FIBRILLATION ABLATION
- PO 87 PULMONARY VEIN ISOLATION PLUS CAVOTRICUSPID ISTHMUS ABLATION SHOWS NO BENEFIT IN ARRHYTHMIA RECURRENCE
- PO 211 INITIAL EXPERIENCE OF ATRIAL FIBRILLATION CATHETER ABLATION IN A LOW-VOLUME CENTER: CRYOABLATION VS RADIOFREQUENCY
- CO 61 ATRIAL GANGLIONATED PLEXI MODIFICATION COMBINED WITH PULMONARY VEIN ISOLATION IN ATHLETES WITH HIGHLY SYMPTOMATIC ATRIAL FIBRILLATION AND BASELINE BRADYCARDIA
- CO 62 NOT SUCH A BLANKING PERIOD AFTER ALL: EARLY RECURRENCE PREDICTS LATE RECURRENCE AFTER AF ABLATION
- CO 65 ISOLATION OF PULMONARY VEINS WITH DUTY-CYCLED CIRCULAR MULTI-POLAR CATHETER

**C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.5 ATRIAL FIBRILLATION - STROKE PREVENTION**

- PO 214 VITAMIN-K ANTAGONISTS VERSUS NON-VITAMIN K ORAL ANTICOAGULANTS IN ELDERLY PATIENTS WITH SEVERE AORTIC STENOSIS AND ATRIAL FIBRILLATION

**C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.9 ATRIAL FIBRILLATION - OTHER**

- PO 212 IMPACT OF INDUCED ATRIAL FIBRILLATION DURING ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA ABLATION

**C. ARRHYTHMIAS AND DEVICE THERAPY -> 06. SUPRAVENTRICULAR TACHYCARDIA (NON-AF) -> 06.4 SUPRAVENTRICULAR TACHYCARDIA (NON-AF) - TREATMENT**

- CO 63 FLUOROLESS CAVOTRICUSPID ISTHMUS ABLATION SUCCESSFULLY ACHIEVES ATRIAL FLUTTER CONTROL

**C. ARRHYTHMIAS AND DEVICE THERAPY -> 07. SYNCOPE AND BRADYCARDIA -> 07.2 SYNCOPE AND BRADYCARDIA - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

- PO 73 EGSYS SCORE - A USEFUL PRACTICE TOOL FOR THE PREDICTION OF REFLEX SYNCOPE?
- PO 94 THE APPLICABILITY OF FAINT SCORE IN SYNCOPE STUDY AND PREDICTION OF PACEMAKER IMPLANTATION.

**C. ARRHYTHMIAS AND DEVICE THERAPY -> 07. SYNCOPE AND BRADYCARDIA -> 07.4 SYNCOPE AND BRADYCARDIA - TREATMENT**

- CO 109 CARDIONEUROABLATION OF NEURALLY MEDIATED REFLEX SYNCOPE: THE EXPERIENCE OF TWO PORTUGUESE CENTRES

**C. ARRHYTHMIAS AND DEVICE THERAPY -> 07. SYNCOPE AND BRADYCARDIA -> 07.5 SYNCOPE AND BRADYCARDIA - PREVENTION**

- PO 75 IMPACT OF A SYNCOPE EDUCATIONAL PREVENTION PROGRAM: A FIRST-YEAR EXPERIENCE

**C. ARRHYTHMIAS AND DEVICE THERAPY -> 07. SYNCOPE AND BRADYCARDIA -> 07.6 SYNCOPE AND BRADYCARDIA - CLINICAL**

- PO 91 APPLICATION OF SYNCOPE GUIDELINES IN A CENTER WITH A TRAUMA-FOCUSED TRIAGE

**C. ARRHYTHMIAS AND DEVICE THERAPY -> 08. VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH (SCD) -> 08.2 VENTRICULAR ARRHYTHMIAS AND SCD - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

- PO 207 FOLLOW-UP OF SUSTAINED VENTRICULAR TACHYCARDIA IN ACUTE CORONARY SYNDROMES
- CO 3 LATE GADOLINIUM ENHANCEMENT IS A STRONG PREDICTOR OF LIFE-THREATENING ARRHYTHMIAS IN PATIENTS WITH NON-ISCHEMIC DILATED CARDIOMYOPATHY UNDERGOING ICD IMPLANTATION FOR PRIMARY PREVENTION OF SUDDEN CARDIAC DEATH
- CO 4 IS IT POSSIBLE TO PREDICT MORTALITY AND RECURRENCE OF VT AFTER ABLATION? - PAINESD RISK SCORE APPLICABILITY VS NEW PREDICTORS
- CO 110 USEFULNESS OF THE NON-INVASIVE ASSESSMENT OF LATE POTENTIALS FOR RISK STRATIFICATION IN BRUGADA SYNDROME

**C. ARRHYTHMIAS AND DEVICE THERAPY -> 08. VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH (SCD) -> 08.3 VENTRICULAR ARRHYTHMIAS AND SCD - DIAGNOSTIC METHODS**

- PO 47 THE PERI-INFARCT "GRAY ZONE" OF MYOCARDIAL FIBROSIS IS A BETTER PREDICTOR OF VENTRICULAR ARRHYTHMIAS THAN DENSE CORE FIBROSIS IN PATIENTS WITH PREVIOUS MYOCARDIAL INFARCTION
- PO 49 BRUGADA SYNDROME: CHARACTERIZATION OF A PORTUGUESE BRUGADA SYNDROME COHORT
- PO 50 QRS DURATION AND FREQUENT PVC: ADDITIONAL FEATURES IN BRUGADA SYNDROME STRATIFICATION
- CO 2 ASSESSMENT OF WAVEFRONT ACTIVATION DURATION ACROSS THE RIGHT VENTRICULAR OUTFLOW TRACT IN PATIENTS WITH IDIOPATHIC PREMATURE VENTRICULAR CONTRACTIONS USING NONINVASIVE ELECTROCARDIOGRAPHIC MAPPING: A VALIDATION STUDY
- CO 106 ACCURACY OF NONINVASIVE ELECTROCARDIOGRAPHIC IMAGING USING ISOPOTENTIAL VERSUS ISOCHRONAL MAP FOR IDENTIFYING THE SITE OF ORIGIN OF VENTRICULAR ARRHYTHMIAS.

**C. ARRHYTHMIAS AND DEVICE THERAPY -> 08. VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH (SCD) -> 08.4 VENTRICULAR ARRHYTHMIAS AND SCD - TREATMENT**

- PO 46 PREDICTORS OF SURVIVAL AND ICD SHOCKS IN NON-ISCHEMIC CARDIOMYOPATHY PATIENTS SUBMITTED TO VENTRICULAR TACHYCARDIA ABLATION
- PO 48 CORRELATION BETWEEN LEFT VENTRICLE WALL-THICKNESS BY CT AND ENDOCARDIAL POTENTIALS IN PATIENTS WITH ISCHEMIC CARDIOPATHY- A PILOT STUDY
- PO 166 EFFECT OF SACUBITRIL/VALSARTAN ON VENTRICULAR ARRHYTHMIA BURDEN IN HEART FAILURE WITH REDUCED EJECTION FRACTION
- PO 206 LONG-TERM IMPACT OF ACTIVATION CIRCUIT-BASED VENTRICULAR TACHYCARDIA ABLATION ON VENTRICULAR ARRHYTHMIA BURDEN
- PO 208 EFFICACY OF MEXILETINE IN THE TREATMENT OF PATIENTS WITH RECURRENT VENTRICULAR ARRHYTHMIAS IN LONG-TERM FOLLOW-UP
- PO 209 IDIOPATHIC VENTRICULAR ARRHYTHMIA ABLATION - A CENTER EXPERIENCE
- PO 210 VENTRICULAR TACHYCARDIA ABLATION IN PATIENTS WITH ISCHAEMIC AND NON-ISCHAEMIC CARDIOMYOPATHY
- CO 1 SINUS RHYTHM ENDOCARDIAL MAPPING FOR CHANNELS' IDENTIFICATION IN ISCHEMIC VENTRICULAR TACHYCARDIA USING A MODIFIED ELECTROPHYSIOLOGICAL TRIAD
- CO 5 EPICARDIAL MAPPING AS FIRST INTENTION APPROACH FOR STRUCTURAL VENTRICULAR TACHYCARDIA ABLATION

**C. ARRHYTHMIAS AND DEVICE THERAPY -> 08. VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH (SCD) -> 08.6 VENTRICULAR ARRHYTHMIAS AND SCD - CLINICAL**

- PO 169 VENTRICULAR TACHYCARDIA ABLATION IN NON-ISCHEMIC CARDIOMYOPATHY
- PO 242 SHANGHAI SCORING SYSTEM FOR RISK STRATIFICATION IN A PORTUGUESE SAMPLE OF BRUGADA SYNDROME PATIENTS

### **C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.1 ANTIBRADYCARDIA PACING**

- PO 86 HIS BUNDLE AND LEFT BUNDLE BRANCH PACING: INITIAL EXPERIENCE
- PO 90 IMPACT OF THE COVID-19 LOCKDOWN IN EMERGENT PACEMAKER IMPLANTATIONS
- PO 244 PREDICTORS OF PACEMAKER DEPENDENCY AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
- CO 36 PROGNOSTIC IMPACT OF PERCENTAGE OF VENTRICULAR PACING IN PATIENTS REQUIRING PACEMAKER IMPLANTATION AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
- CO 39 PACING VENTRICULAR NA REGIÃO DO RAMO ESQUERDO - EXPERIÊNCIA INICIAL

### **C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.2 IMPLANTABLE CARDIOVERTER / DEFIBRILLATOR**

- PO 95 SAFETY OF SAME-DAY VS NEXT-DAY DISCHARGE AFTER CIED: A SINGLE-CENTER EXPERIENCE
- PO 168 THE EFFECTS OF SACUBITRIL-VALSARTAN ON ICD INDICATION IN PATIENTS WITH HEART FAILURE
- PO 170 PRIMARY PREVENTION IMPLANTATION OF CARDIOVERTER DEFIBRILLATORS IN TRULY ASYMPTOMATIC PATIENTS - SHOULD WE RETHINK CURRENT RECOMMENDATIONS?
- CO 37 HEART RATE SCORE: A SIMPLE AND USEFUL PREDICTOR FOR CLINICAL OUTCOMES IN HEART FAILURE

### **C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.3 CARDIAC RESYNCHRONIZATION THERAPY**

- PO 93 LOWER RATE LIMIT IN CARDIAC RESYNCHRONIZATION THERAPY-DEFIBRILLATORS: IS LOWER BETTER?
- CO 38 WHAT IS THERE TO EARN WITH A CRT IMPLANTATION? PREDICTIVE FACTORS OF MORTALITY OR CLINICAL DETERIORATION IN PATIENTS RECEIVING CARDIAC RESYNCHRONIZATION THERAPY BASED ON PRE-IMPLANT FACTORS.
- CO 40 APICAL VERSUS SEPTAL PACING AND UPGRADE TO CARDIAC RESYNCHRONIZATION THERAPY: WHAT ARE THE ODDS?

### **C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.4 HOME AND REMOTE PATIENT MONITORING**

- PO 167 TELEMONITORING IN HEART FAILURE MANAGEMENT - THE EXPERIENCE OF A REMOTE CENTER
- PO 215 RESPIRATORY DISTURBANCE INDEX AS A PREDICTOR OF ATRIAL FIBRILLATION

### **C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.6 DEVICE THERAPY - OTHER**

- PO 88 USEFULNESS OF THE PHYSIOLOGICAL VDD PACEMAKER IN ELDERLY PATIENTS WITH NORMAL SINUS RHYTHM
- PO 89 ACESSO VENOSO AXILAR PARA IMPLANTAÇÃO DE DISPOSITIVOS DE PACING - EXPERIÊNCIA DE UM CENTRO

### **D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.2 CHRONIC HEART FAILURE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

- PO 18 HEART FAILURE- ONE ONLY DISEASE OR A GROUP OF DIFFERENT ENTITIES?
- PO 19 HEART-KIDNEY CROSSTALK: HEART FAILURE AND THE RISK OF CARDIOVASCULAR EVENTS AND END STAGE RENAL DISEASE IN YOUNG TYPE 2 DIABETIC PATIENTS
- PO 59 HEMODYNAMIC GAIN INDEX: A NEW PROGNOSTIC MARKER IN HEART FAILURE?
- PO 60 THE HFFI, A NEW FRAILTY INDEX FOR ASSESSING LONG-TERM OUTCOMES IN HEART FAILURE
- PO 100 THE NEED FOR DIURETIC THERAPY IN SPITE OF HEART FAILURE WITH REDUCED EJECTION FRACTION FOUNDATIONAL THERAPY: A NEW MARKER OF ADVERSE PROGNOSIS?

- PO 139 PROGNOSTIC IMPACT OF RIGHT VENTRICULAR FUNCTION IN ADVANCED HEART FAILURE
- PO 140 FUNCTIONAL MITRAL REGURGITATION IN ADVANCED HEART FAILURE
- PO 176 HYPERKALEMIA AND HEART FAILURE WITH REDUCED EJECTION FRACTION: PREVALENCE AND PROGNOSTIC IMPACT ON A PORTUGUESE POPULATION
- PO 179 HIGH PREVALENCE OF POLYCYTHEMIA IN HEART FAILURE PATIENTS
- PO 217 IMPACT OF SGLT2 INHIBITORS ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
- CO 98 SACUBITRIL-VALSARTAN VERSUS ACEI IN LEFT VENTRICULAR REVERSE REMODELLING AND CARDIOVASCULAR OUTCOMES
- CO 127 I NEED HELP: FROM THE ACRONYM TO THE RISK SCORE FOR PREDICTING ADVERSE OUTCOMES IN CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION
- CO 128 CARDIORENAL SYNDROME AND DEATH RISK IN PATIENTS WITH HEART FAILURE OR CHRONIC KIDNEY DISEASE: AN UNMET CARDIORENAL NEED?
- CO 129 EXERCISE OSCILLATORY VENTILATION - IS THERE MORE TO IT THAN JUST UPS AND DOWNS?

#### **D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.3 CHRONIC HEART FAILURE - DIAGNOSTIC METHODS**

- PO 20 LEFT BUNDLE BRANCH BLOCK - IS IT POSSIBLE TO PREDICT LEFT VENTRICLE DYSFUNCTION?
- PO 137 EVALUATION OF RV-ARTERIAL COUPLING IN ADVANCED HEART FAILURE
- CO 47 BNP VERSUS NT-PROBNP FOR ECHOCARDIOGRAPHIC AND HEMODYNAMIC PARAMETERS PREDICTION IN HEART TRANSPLANTED PATIENTS
- CO 49 CAN ECHOCARDIOGRAPHIC PARAMETERS EFFECTIVELY PREDICT ELEVATED PCWP IN HEART TRANSPLANT PATIENTS?
- CO 57 ONLY RIGHT VENTRICULAR FUNCTION PARAMETERS CAN PREDICT ACUTE CELLULAR REJECTION IN HEART TRANSPLANT PATIENTS?

#### **D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.4 CHRONIC HEART FAILURE - TREATMENT**

- PO 16 CLINICAL DETERMINANTS AND BARRIERS TO CARDIAC REHABILITATION ENROLMENT OF HEART FAILURE PATIENTS
- PO 96 LEVOSIMENDAN IN OUTPATIENTS WITH ADVANCED HEART FAILURE: SINGLE-CENTER EXPERIENCE OF 200 INTERMITTENT PERFUSIONS
- PO 97 SACUBITRIL-VALSARTAN: THE EARLIER, THE BETTER?
- PO 98 PREDICTORS OF SACUBITRIL-VALSARTAN TARGET DOSE ACHIEVEMENT IN A REAL-WORLD POPULATION
- PO 99 MAXIMUM DOSE SACUBITRIL/VALSARTAN IN THE ELDERLY PEOPLE WITH HEART FAILURE AND REDUCED EJECTION FRACTION.
- PO 138 RESPONSE AND LONG-TERM OUTCOMES WITH RESYNCHRONIZATION THERAPY: DOES HEART FAILURE ETIOLOGY MATTER?
- PO 216 DAPAGLIFLOZIN IN HEART FAILURE WITH REDUCED EJECTION FRACTION: A RANDOMIZED CONTROLLED TRIAL
- PO 218 SGLT2 INHIBITORS IN HEART FAILURE WITH REDUCED EJECTION FRACTION: THEIR BIOLOGICAL PROPERTIES GOES WELL BEYOND A SMART DIURETIC EFFECT
- PO 219 SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS: THE GLUE FOR HEART FAILURE WITH REDUCED EJECTION FRACTION FOUNDATIONAL THERAPY
- PO 220 DAPAGLIFOZIN IN THE REAL WORLD - WHAT IS THE IMPACT ON HEART FAILURE WITH REDUCED EJECTION FRACTION ALREADY UNDER OPTIMIZED THERAPY?
- CO 56 CARDIAC RESYNCHRONIZATION THERAPY IN ATRIAL FIBRILLATION: RESPONSE AND LONG-TERM OUTCOMES
- CO 58 THE EFFECT OF HEART FAILURE THERAPY IN PATIENTS WITH MILDLY REDUCED EJECTION FRACTION: A NETWORK META-ANALYSIS
- CO 59 HEART FAILURE WITH REDUCED EJECTION FRACTION FOUNDATIONAL THERAPY: WHY SHOULD WE FOLLOW THE 2021 EUROPEAN SOCIETY OF CARDIOLOGY HEART FAILURE GUIDELINES AND FORGET THE PREVIOUS THERAPEUTIC ALGORITHM?

- CO 60 MAIN LIMITING FACTORS OF FOUNDATIONAL THERAPY INTRODUCTION IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
- CO 96 LEFT VENTRICULAR STRAIN IMAGING IN HEART FAILURE PATIENTS UNDER SACUBITRIL/VALSARTAN THERAPY
- CO 97 SAFETY AND EFFECTIVENESS OF SACUBITRIL-VALSARTAN IN A REAL-WORLD POPULATION

#### **D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.5 CHRONIC HEART FAILURE - PREVENTION**

- PO 177 SERUM URIC ACID LEVELS PROGNOSTIC VALUE IN CHRONIC HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION
- CO 46 REMOTE INVASIVE MONITORING OF PULMONARY ARTERY PRESSURE IN PATIENTS WITH HEART FAILURE: INITIAL EXPERIENCE OF A TERTIARY CARE CENTER
- CO 99 DOES DAPAGLIFLOZIN IMPROVE CARDIOPULMONARY PERFORMANCE OF NON-DIABETIC HEART FAILURE PATIENTS?

#### **D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.6 CHRONIC HEART FAILURE - CLINICAL**

- PO 17 PHYSICAL ACTIVITY AND HEART FAILURE: A FORGOTTEN INDICATOR
- CO 48 NT-PROBNP FOR FUNCTIONAL CAPACITY ASSESSMENT IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
- CO 126 TRANSTHYRETIN AMYLOID CARDIOMYOPATHY: A 2-YEAR SINGLE-CENTRE EXPERIENCE

#### **D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.7 CHRONIC HEART FAILURE - OTHER**

- CO 50 LONG-TERM BENEFITS OF NON-INVASIVE TELEMONITORING IN PATIENTS WITH CHRONIC HEART FAILURE

#### **D. HEART FAILURE -> 11. ACUTE HEART FAILURE -> 11.2 ACUTE HEART FAILURE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

- PO 56 DOES BLOOD UREA NITROGEN-TO-CREATININE RATIO PREDICT OUTCOMES IN DECOMPENSATED HEART FAILURE?
- PO 57 C2HEST SCORE - HEART FAILURE RISK SCORE: PREDICTIVE VALUE FOR ONE-YEAR MORTALITY AND RE-ADMISSION AFTER DISCHARGE
- PO 58 GWTG-HF SCORE VS AHEAD SCORE: WHICH SCORES BETTER?
- CO 100 SGLT2 INHIBITOR INITIATION IN PATIENTS HOSPITALIZED FOR ACUTE HEART FAILURE: DOES IT STILL MATTER WHEN PATIENTS ARE STRICTLY FOLLOWED AFTER DISCHARGE?
- CO 130 MODIFIED VERSUS CONVENTIONAL BODY MASS INDEX IN PATIENTS ADMITTED DUE TO ACUTE HEART FAILURE: ASSOCIATION WITH ADVERSE PROGNOSIS.

#### **D. HEART FAILURE -> 11. ACUTE HEART FAILURE -> 11.3 ACUTE HEART FAILURE - DIAGNOSTIC METHODS**

- PO 178 IRON STATUS VARIATION IN ACUTE HEART FAILURE: A PROSPECTIVE STUDY - RELEASE OF PRELIMINARY DATA

#### **D. HEART FAILURE -> 11. ACUTE HEART FAILURE -> 11.6 ACUTE HEART FAILURE - CLINICAL**

- PO 136 PATIENTS ADMITTED WITH ACUTE HEART FAILURE AT AN INTENSIVE CARE DEPARTMENT - COMPARISON BETWEEN THE CLINICAL PROFILES OF PATIENTS WITH PRESERVED VS. REDUCED LEFT VENTRICULAR EJECTION FRACTION
- PO 180 PLASMA VOLUME VARIATION AND GLOMERULAR FILTRATION RATE IN HEART FAILURE ADMISSIONS

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->  
12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.2 CORONARY ARTERY DISEASE - EPIDEMIOLOGY,  
PROGNOSIS, OUTCOME**

- PO 27 RELATIONSHIP BETWEEN THE BLOOD PRESSURE AND THE LONG-TERM PROGNOSIS IN A COHORT OF CORONARY PATIENTS
- PO 28 LIPOPROTEIN(A) AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH CORONARY ARTERY DISEASE AND IMPAIRED GLUCOSE METABOLISM
- CO 89 WORKLOAD-INDEXED BLOOD PRESSURE RESPONSE PREDICTS CARDIOVASCULAR EVENTS IN CORONARY ARTERY DISEASE

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->  
12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.3 CORONARY ARTERY DISEASE - DIAGNOSTIC  
METHODS**

- PO 29 MY PATIENT HAS A POSITIVE ISCHEMIA TEST: WILL HE HAVE OBSTRUCTIVE CORONARY ARTERY DISEASE?
- PO 30 EXERCISE ELECTROCARDIOGRAM - A DIAGNOSTIC TEST OF THE PAST?

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->  
12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.4 CORONARY ARTERY DISEASE - TREATMENT**

- CO 27 CORONARY SINUS REDUCER DEVICE FOR THE TREATMENT OF REFRACTORY ANGINA THERAPY. A MULTICENTRIC INITIAL EXPERIENCE.

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->  
12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.5 CORONARY ARTERY DISEASE - PREVENTION**

- PO 26 COMPARISON BETWEEN THE EUROPEAN SCORE AND THE UPDATED SCORE2 FOR CARDIOVASCULAR OUTCOMES

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->  
12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.6 CORONARY ARTERY DISEASE - CLINICAL**

- PO 186 CHRONOTROPIC INCOMPETENCE- STILL A SUITABLE INDICATOR?

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->  
13. ACUTE CORONARY SYNDROMES -> 13.1 ACUTE CORONARY SYNDROMES - PATHOPHYSIOLOGY  
AND MECHANISMS**

- CO 29 CIRCADIAN RHYTHM IMPACT IN REMOTE ISCHEMIC CONDITIONING IN MYOCARDIAL INFARCTION

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->  
13. ACUTE CORONARY SYNDROMES -> 13.2 ACUTE CORONARY SYNDROMES - EPIDEMIOLOGY,  
PROGNOSIS, OUTCOME**

- PO 32 HOW MUCH MORE HYPERGLYCEMIC IS MY MYOCARDIAL INFRACTION PATIENT AND WHY DOES IT MATTER?
- PO 43 OUTCOMES OF PATIENTS WITH ACUTE UNPROTECTED LEFT MAIN CORONARY OCCLUSION: A MULTICENTRE STUDY
- PO 44 ACUTE MYOCARDIAL INFARCTION IN PATIENTS WITH ACUTE OCCLUSION OF THE LEFT MAIN CORONARY ARTERY - DOES AGE MATTER?
- PO 70 UTILITY OF THE AGE SHOCK INDEX IN PATIENTS WITH AN ACUTE CORONARY SYNDROME
- PO 108 CORONARY RESTENOSIS: SEVENTEEN YEARS SUMMARIZED...
- PO 109 DELAY BETWEEN SYMPTOMS ONSET AND SEEKING MEDICAL CARE - DOES INITIAL RHYTHM PLAYS A ROLE?

- PO 110** SHOULD WE STAY OR SHOULD WE GO: ASSESSMENT OF THE NEED FOR THE IMPLANTATION OF A DEFINITE PACEMAKER IN A POPULATION OF ACUTE CORONARY SYNDROME THAT EVOLVED IN ADVANCED ATRIOVENTRICULAR BLOCK.
- PO 149** THE OBESITY PARADOX IN ACUTE ST-ELEVATED MYOCARDIAL INFARCTION
- PO 150** IS SYMPTOMS-BALLOON-TIME A BETTER PROGNOSTIC PREDICTOR?
- PO 161** CHARACTERIZATION OF RISK FACTORS AND MORTALITY IN YOUNG PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
- PO 162** GENDER DISPARITIES IN ACUTE MYOCARDIAL INFARCTION - STILL AN UNSOLVED PUZZLING ISSUE
- PO 163** MACE IN MYOCARDIAL INFARCTION WITH NON-OBSTRUCTIVE CORONARY ARTERIES: PREDICTORS AND PROGNOSIS
- PO 164** DISCRIMINATORY CAPACITY OF ACTION-ICU ACCORDING TO AGE - A SCORE FOR ALL?
- PO 187** ACUTE KIDNEY INJURY ON ADMISSION FOR ACUTE CORONARY SYNDROME AS A PREDICTOR OF 1-YEAR MORTALITY
- PO 189** C-REACTIVE PROTEIN AS A PROGNOSTIC MARKER IN MYOCARDIAL INFARCTION WITH NON-OBSTRUCTIVE CORONARY ARTERIES
- CO 7** STEMI WITH MID-RANGE EJECTION FRACTION - A GROUP OF INTERMEDIATE RISK NOT TO BE FORGOTTEN
- CO 8** PRECISE-DAPT SCORE FOR BLEEDING PREDICTION AFTER ACUTE CORONARY SYNDROME IN PATIENTS TREATED WITH PERCUTANEOUS CORONARY INTERVENTION FOR MULTIVESSEL DISEASE
- CO 9** RESUSCITATED CARDIAC ARREST IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION IS ASSOCIATED WITH INCREASED INFARCT SIZE AND WORSE OUTCOMES
- CO 68** ACUTE TOTAL OCCLUSION OF THE UNPROTECTED LEFT MAIN CORONARY ARTERY - PATIENT CHARACTERISTICS AND OUTCOMES
- CO 69** MECHANICAL CIRCULATORY SUPPORT DEVICES IN LEFT MAIN OCCLUSION: A MULTICENTER STUDY FROM 2008 TO 2020
- CO 70** AMI DUE TO LEFT MAIN CORONARY ARTERY OCCLUSION: A COMPARATIVE MULTICENTER STUDY FROM 2008 TO 2020
- CO 87** NEW-ONSET OF ATRIAL FIBRILLATION IN ST-ELEVATION MYOCARDIAL INFARCTION
- CO 88** FUNCTIONAL IRON DEFICIENCY IN ACUTE CORONARY SYNDROMES: PREVALENCE AND PROGNOSTIC IMPACT
- CO 90** LONG-TERM PROGNOSIS OF MYOCARDIAL INFARCTION WITH NON-OBSTRUCTIVE CORONARY ARTERIES VERSUS MYOCARDIAL INFARCTION WITH OBSTRUCTIVE CORONARY ARTERY DISEASE

## **E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 13. ACUTE CORONARY SYNDROMES -> 13.3 ACUTE CORONARY SYNDROMES - DIAGNOSTIC METHODS**

- PO 165** FINDING TAKOTSUBO CARDIOMYPATHY ON CARDIAC MAGNETIC RESONANCE
- PO 190** PERFORMANCE OF DIFFERENT HIGH SENSITIVITY CARDIAC TROPONIN ASSAYS IN PATIENTS WITH SUSPECTED ACUTE CORONARY SYNDROME
- CO 72** TÉCNICOS DE CARDIOPNEUMOLOGIA NO SERVIÇO DE URGÊNCIA NA PRESTAÇÃO DE CUIDADOS AOS DOENTES COM SÍNDROME CORONÁRIA AGUDA

## **E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 13. ACUTE CORONARY SYNDROMES -> 13.4 ACUTE CORONARY SYNDROMES - TREATMENT**

- PO 45** EMERGENT CORONARY ANGIOGRAPHY IN A 90-PLUS POPULATION - OUTCOMES AT 5-YEARS FOLLOW-UP
- PO 66** CABG VS PCI FOR DIABETIC PATIENTS WITH NON-ST ELEVATION ACS: IN-HOSPITAL OUTCOMES
- PO 67** CABG VS PCI FOR DIABETIC PATIENTS WITH NON-ST ELEVATION ACS: ONE-YEAR OUTCOMES
- PO 69** BLEEDING RISK IN PATIENTS WITH NSTEMI: P2Y12 INHIBITORS PRESCRIPTION PATTERNS FROM 2019 TO 2021
- PO 146** THE IMPACT OF OUTPATIENT EMERGENCY MEDICAL SYSTEM IN STEMI PATIENTS UNDERGOING PRIMARY ANGIOPLASTY: A SINGLE-CENTRE EXPERIENCE
- PO 147** AT THE OUTER EDGE OF STEMI TIME: EVEN AFTER 12 HOURS, THE CLOCK KEEPS TICKING.
- PO 148** STEMI TREATMENT IN REMOTE LOCATIONS: AN UNCOMMON REALITY
- CO 10** SGLT2 INHIBITION IN ACUTE MYOCARDIAL INFARCTION WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION
- CO 30** EFFECTIVENESS AND SAFETY OF P2Y12 INHIBITOR PRETREATMENT FOR PRIMARY PCI IN STEMI: SYSTEMATIC REVIEW AND META-ANALYSIS

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->  
13. ACUTE CORONARY SYNDROMES -> 13.5 ACUTE CORONARY SYNDROMES - PREVENTION**

**PO 107** DO PATIENTS WITH CARDIOVASCULAR RISK FACTORS REALIZE WHAT IS AT RISK?

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->  
13. ACUTE CORONARY SYNDROMES -> 13.6 ACUTE CORONARY SYNDROMES - CLINICAL**

**PO 42** A MULTICENTER REGISTRY OF ACUTE LEFT MAIN CORONARY ARTERY OCCLUSION: DIABETES MATTERS?

**PO 68** SYMPTOMS AT NSTEMI PRESENTATION: DO PATIENT'S COMPLAINTS PREDICT THE OUTCOME?

**PO 106** PHYSICAL EXERCISE ACTIVITY TRENDS IN ACUTE MYOCARDIAL INFARCTION PATIENTS - WHERE DO WE STAND?

**CO 6** ACUTE MYOCARDIAL INFARCTION DURING COVID-19 ERA: PATIENT CHARACTERISTICS, PRESENTATION AND OUTCOMES

**CO 86** CORRELATION BETWEEN NSTEMI-ACS RISK SCORES WITH SYNTAX: CAN WE PREDICT CORONARY LESION COMPLEXITY BEFORE ANGIOGRAPHY?

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->  
14. ACUTE CARDIAC CARE -> 14.2 ACUTE CARDIAC CARE - PREHOSPITAL AND EMERGENCY DEPARTMENT CARE**

**PO 188** MODIFIED M-CHA2DS2-VASC SCORE PREDICTS MORTALITY AT EMERGENCY DEPARTMENT ADMISSION IN COVID-19 PATIENTS

**CO 26** PATIENT DELAY IN ACUTE MYOCARDIAL INFARCTION - A LONG JOURNEY STILL AHEAD

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->  
14. ACUTE CARDIAC CARE -> 14.3 ACUTE CARDIAC CARE - CCU, INTENSIVE, AND CRITICAL CARDIOVASCULAR CARE**

**PO 41** MANAGEMENT OF ACUTE LEFT MAIN OCCLUSION IN SURGICAL AND NON-SURGICAL CENTERS: A MULTICENTER STUDY

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->  
14. ACUTE CARDIAC CARE -> 14.4 ACUTE CARDIAC CARE - CARDIOGENIC SHOCK**

**CO 28** PERIPHERAL VENOARTERIAL EXTRACORPOREAL MEMBRANE OXYGENATION FOR REFRACTORY CARDIOGENIC SHOCK: SINGLE-CENTER EXPERIENCE

**CO 66** CARDIOGENIC SHOCK COMPLICATING ACUTE MYOCARDIAL INFARCTION DUE TO LEFT MAIN CORONARY ARTERY OCCLUSION: A MULTICENTRE STUDY

**E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->  
14. ACUTE CARDIAC CARE -> 14.5 ACUTE CARDIAC CARE - CARDIAC ARREST**

**CO 67** CARDIAC ARREST IN PATIENTS WITH ACUTE LEFT MAIN STEM OCCLUSION: A REAL-WORLD MULTICENTER REGISTRY

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->  
15. VALVULAR HEART DISEASE -> 15.1 VALVULAR HEART DISEASE - PATHOPHYSIOLOGY AND MECHANISMS**

**PO 79** LEFT VENTRICULAR REVERSE REMODELING IN POST OPERATIVE AORTIC STENOSIS PATIENTS: PREVALENCE AND PREDICTOR(S)

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->  
15. VALVULAR HEART DISEASE -> 15.2 VALVULAR HEART DISEASE - EPIDEMIOLOGY, PROGNOSIS,  
OUTCOME**

- PO 36 TRICUSPID REGURGITATION - PATIENTS CHARACTERISTICS, TREATMENT AND OUTCOMES
- PO 37 IMPACT OF CONCOMITANT MITRAL AND TRICUSPID REGURGITATION IN PATIENTS WITH SIGNIFICANT CHRONIC AORTIC REGURGITATION
- PO 80 SHOULD CONTRACTILE RESERVE BE A DECISIVE FACTOR ON SEVERE AORTIC VALVE INTERVENTION?
- PO 117 AORTIC STENOSIS - THE LUNG IS OFTEN OVERLOADED, BUT WHAT ABOUT THE LIVER?
- PO 118 AORTIC VALVE CALCIUM SCORE AND PERI-PROTHESIS LEAKS AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION: IS THERE A HINT?
- PO 120 PREVALENCE, MANAGEMENT, AND PROGNOSIS OF PATIENTS WITH SEVERE AORTIC STENOSIS AND REDUCED EJECTION FRACTION
- CO 15 CONTRACTILE RESERVE: A KEY FACTOR IN AORTIC STENOSIS
- CO 94 FUNCTIONAL MITRAL REGURGITATION: KEEPING COHERENCE WITH THE ASE GRADING GUIDELINES, WHICH PROPORTIONALITY CONCEPT BEST PREDICTS PROGNOSIS IN THE REAL WORLD?

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->  
15. VALVULAR HEART DISEASE -> 15.3 VALVULAR HEART DISEASE - DIAGNOSTIC METHODS**

- PO 76 IS FLOW BETTER IN ML/M2 OR ML/S - A PRACTICAL REFLECTION ON AORTIC STENOSIS
- PO 116 NORMAL FLOW, LOW GRADIENT AORTIC STENOSIS - IS LVOT THE DETERMINANT?
- CO 12 A PRELIMINARY ANALYSIS REGARDING FUNCTIONAL MITRAL REGURGITATION GRADING WITH ECHOCARDIOGRAPHY AND CMR: IN SEARCH OF SIMILARITIES AND RESOLVING DISCORDANCES.
- CO 144 DOES MY TAVR PATIENT HAVE CARDIAC AMYLOIDOSIS?

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->  
15. VALVULAR HEART DISEASE -> 15.4 VALVULAR HEART DISEASE - TREATMENT**

- PO 38 CLINICAL AND ECHOCARDIOGRAPHIC PREDICTORS OF WORSENING MITRAL REGURGITATION AFTER PERCUTANEOUS MITRAL VALVE REPAIR
- PO 39 COVID-19 IMPACT ON REFERRALS, TREATMENT DECISIONS AND TIME ON THE WAITING LIST FOR VALVULAR HEART DISEASE INTERVENTION
- PO 40 IS WILKINS SCORE OVER 9 A DEFINITIVE LIMIT TO FAVORABLE LONG-TERM SUCCESS IN PERCUTANEOUS VALVE COMMISSUROTOMY?
- PO 78 FLOW RATE IN SEVERE AORTIC STENOSIS - A GOOD PROGNOSTIC MARKER FOR PERCUTANEOUS VALVE IMPLANTATION?
- PO 119 TAVI - MULTIDIMENSIONAL EARLY BENEFITS ON ELDERLY PATIENTS
- CO 13 CLINICAL AND ECHOCARDIOGRAPHIC VERY LONG-TERM OUTCOMES AFTER PERCUTANEOUS MITRAL BALLOON VALVULOPLASTY IN SEVERE RHEUMATIC MITRAL STENOSIS
- CO 14 PERCUTANEOUS VALVE COMMISSUROTOMY FOR MITRAL STENOSIS PATIENTS: A 20 YEARS FOLLOW-UP
- CO 92 TRANSCATHETER AORTIC VALVE IMPLANTATION OUTCOMES IN PATIENTS WITH LOW FLOW - LOW GRADIENT AORTIC STENOSIS
- CO 146 BIOLOGICAL OR MECHANICAL AORTIC PROSTHESES IN PATIENTS AGED 40-60 YEARS : A SINGLE CENTRE EXPERIENCE

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->  
15. VALVULAR HEART DISEASE -> 15.6 VALVULAR HEART DISEASE - CLINICAL**

- PO 25 ELECTROCARDIOGRAPHIC ASSESSMENT OF LVH IN AORTIC STENOSIS PATIENTS: HOW WELL DOES IT CORRELATE WITH MYOCARDIAL MASS?

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 15. VALVULAR HEART DISEASE -> 15.7 VALVULAR HEART DISEASE - OTHER**

PO 77 LEFT VENTRICULAR REVERSE REMODELING AFTER TAVR FOR AORTIC STENOSIS

CO 11 REVERSE LEFT VENTRICULAR REMODELING AFTER AORTIC VALVE REPLACEMENT FOR AORTIC STENOSIS: SYSTEMATIC REVIEW AND META-ANALYSIS

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 16. INFECTIVE ENDOCARDITIS -> 16.2 INFECTIVE ENDOCARDITIS - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

PO 196 ENDOCARDITIS IN-HOSPITAL MORTALITY: WHAT CAN WE EXPECT?

PO 198 INFECTIVE ENDOCARDITIS: HAS ITS PROGNOSIS CHANGED 5 YEARS AFTER THE NEW ESC GUIDELINES?

PO 199 PREDICTORS OF IN-HOSPITAL MORTALITY IN INFECTIOUS ENDOCARDITIS

PO 200 PREDICTORS OF RECURRENCE IN INFECTIOUS ENDOCARDITIS

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 16. INFECTIVE ENDOCARDITIS -> 16.6 INFECTIVE ENDOCARDITIS - CLINICAL**

PO 33 SHOULD WE TRUST SCORES TO RULE OUT TRANSESOPHAGIC ECHOCARDIOGRAPHY IN PATIENTS WITH STAPHYLOCOCCUS AUREUS BACTERIEMIA?

PO 197 INFECTIVE ENDOCARDITIS: EXPERIENCE OF THE LAST 20 YEARS

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 17. MYOCARDIAL DISEASE -> 17.1 MYOCARDIAL DISEASE - PATHOPHYSIOLOGY AND MECHANISMS**

PO 127 CHRONOTROPIC INCOMPETENCE AND ITS RELATION TO EXERCISE CAPACITY IN HYPERTROPHIC CARDIOMYOPATHY

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 17. MYOCARDIAL DISEASE -> 17.2 MYOCARDIAL DISEASE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

PO 34 CARDIAC MAGNETIC RESONANCE IN MYOCARDITIS: BESIDES THE DIAGNOSIS?

PO 35 IMPLICATIONS OF SEPTAL LATE GADOLINIUM ENHANCEMENT IN PATIENTS WITH ACUTE MYOCARDITIS

PO 126 RELATIVE APICAL LONGITUDINAL STRAIN - A POWERFUL TOOL TO PREDICT LONG-TERM OUTCOMES IN TRANSTHYRETIN AMYLOID CARDIOMYOPATHY PATIENTS

PO 171 PREDICTORS OF IN-HOSPITAL LEFT VENTRICLE FUNCTION RECOVERY IN TAKOTSUBO SYNDROME

PO 173 TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM): A POTENTIAL ROLE FOR CARDIOPULMONARY EXERCISE TESTING

PO 175 SPONGY MYOCARDIUM OR LEFT VENTRICULAR NONCOMPACTION: WHICH FACTORS IMPACT PROGNOSIS?

CO 114 MYOCARDIAL DEFORMATION ANALYSIS USING CARDIAC MAGNETIC RESONANCE IN APICAL HYPERTROPHIC CARDIOMYOPATHY

CO 115 REDUCED 3D-LEFT ATRIUM EJECTION FRACTION PREDICTS DEVELOPMENT OF ATRIAL FIBRILLATION IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY

CO 142 MECHANICAL DISPERSION: CAN IT PREDICT THE OCCURRENCE OF VENTRICULAR ARRHYTHMIAS IN FABRY DISEASE?

CO 143 CLINICAL AND ECHOCARDIOGRAPHIC PROGNOSTIC FACTORS IN WILD TYPE TRANSTHYRETIN CARDIAC AMYLOIDOSIS

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 17. MYOCARDIAL DISEASE -> 17.3 MYOCARDIAL DISEASE - DIAGNOSTIC METHODS**

PO 128 COMPARISON OF LEFT VENTRICULAR STRAIN OBTAIN BY CARDIAC MAGNETIC RESONANCE 3D FEATURE TRACKING AND 3D SPECKLE TRACKING ECHOCARDIOGRAPHY, IN HYPERTROPHIC CARDIOMYOPATHY

- PO 129 CORONARY FLOW VELOCITY RESERVE IN HYPERTROPHIC CARDIOMYOPATHY: RELATION WITH NONUNIFORM MYOCARDIAL HYPERTROPHY
- PO 130 SIGNALLING AMYLOIDOSIS DIAGNOSIS WITH RED FLAGS
- PO 174 TRANSTHYRETIN CARDIAC AMYLOIDOSIS DUE TO RARE MUTATIONS IN PORTUGUESE PATIENTS
- CO 91 SEGMENTAL ANALYSIS OF MICROVASCULAR DYSFUNCTION AND TISSUE CHARACTERIZATION IN HYPERTROPHIC CARDIOMYOPATHY BY MAGNETIC RESONANCE IMAGING
- CO 112 THREE DIMENSIONAL MYOCARDIAL DEFORMATION PARAMETERS ARE ASSOCIATED WITH FUNCTIONAL CAPACITY IN HYPERTROPHIC CARDIOMYOPATHY
- CO 113 MICROVASCULAR DYSFUNCTION IS ASSOCIATED WITH IMPAIRED MYOCARDIAL WORK IN OBSTRUCTIVE AND NONOBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: A MULTIMODALITY APPROACH
- CO 141 MICROVASCULAR DYSFUNCTION AND MYOCARDIAL FIBROSIS IMPACT ON LEFT VENTRICULAR MYOCARDIAL DEFORMATION IN HYPERTROPHIC CARDIOMYOPATHY - PER SEGMENT ANALYSIS BY MAGNETIC RESONANCE IMAGING

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->  
17. MYOCARDIAL DISEASE -> 17.4 MYOCARDIAL DISEASE - TREATMENT**

- CO 111 ECHOCARDIOGRAPHIC OUTCOMES OF OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY AFTER PERCUTANEOUS ASA: A SINGLE CENTRE EXPERIENCE
- CO 147 MIECTOMIA MORROW NA MIOCARDIOPATIA HIPETRÓFICA OBSTRUTICA: RESULTADOS A CURTO E LONGO PRAZO DE UM CENTRO REFERÊNCIA

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->  
17. MYOCARDIAL DISEASE -> 17.6 MYOCARDIAL DISEASE - CLINICAL**

- CO 145 MYOCARDITIS, PERICARDITIS AND COVID-19 VACCINATION - A TRUE CONCERN?

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->  
17. MYOCARDIAL DISEASE -> 17.7 MYOCARDIAL DISEASE - OTHER**

- PO 172 TAKOTSUBO SYNDROME: TEN-YEAR EXPERIENCE FROM A SINGLE CENTER

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->  
19. TUMORS OF THE HEART -> 19.3 TUMORS OF THE HEART - DIAGNOSTIC METHODS**

- PO 61 PAPILLARY FIBROELASTOMAS - DIAGNOSTIC CHALLENGES AND CLINICAL AND MORPHOLOGIC FEATURES

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->  
19. TUMORS OF THE HEART -> 19.6 TUMORS OF THE HEART - CLINICAL**

- PO 62 CARDIAC MYXOMA EMBOLIC EVENTS: CHARACTERIZATION AND PREDICTORS

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->  
20. CONGENITAL HEART DISEASE AND PEDIATRIC CARDIOLOGY -> 20.2 CONGENITAL HEART DISEASE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

- PO 82 OPTIMIZING ADULT CONGENITAL HEART DISEASE CARE: EXPERIENCE OF AN ORGANIZED PROGRAM IN A REMOTE NON SPECIALIST CENTER
- PO 84 LONG-TERM OUTCOME IN FONTAN PROCEDURE PATIENTS: THE DESTINATION THERAPY OR A BRIDGE TO TRANSPLANT?
- CO 116 PREGNANCY OUTCOMES IN WOMEN WITH SEVERE CONGENITAL HEART DISEASE - A SPECIALIZED CENTRE EXPERIENCE
- CO 117 IMPACT OF COVID-19 IN ADULT PATIENTS WITH CONGENITAL HEART DISEASE

- CO 120 THE WORLD UPSIDE DOWN - AFTER 20 YEARS FOLLOW-UP OF DEXTRO-TRANSPOSITION OF THE GREAT ARTERIES  
CO 140 CARDIOPULMONARY EXERCISE TESTING IN REPAIRED TETRALOGY OF FALLOT AND RIGHT VENTRICLE DILATATION

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->  
20. CONGENITAL HEART DISEASE AND PEDIATRIC CARDIOLOGY -> 20.4 CONGENITAL HEART  
DISEASE - TREATMENT**

- PO 81 NOAC IN ADULT CONGENITAL HEART DISEASE PATIENTS: A SINGLE-CENTER EXPERIENCE  
PO 85 ANOMALOUS AORTIC ORIGIN OF THE RIGHT CORONARY ARTERY: SINGLE CENTRE EXPERIENCE  
CO 119 BETA-BLOCKERS: A MODIFIER OF THE NATURAL HISTORY OF BICUSPID AORTIC VALVES?

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->  
20. CONGENITAL HEART DISEASE AND PEDIATRIC CARDIOLOGY -> 20.5 CONGENITAL HEART  
DISEASE - PREVENTION**

- CO 118 CARDIOPULMONARY EXERCISE TESTING IN REPAIRED TETRALOGY OF FALLOT AND SUPRAVENTRICULAR ARRHYTHMIAS

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->  
20. CONGENITAL HEART DISEASE AND PEDIATRIC CARDIOLOGY -> 20.6 CONGENITAL HEART  
DISEASE - CLINICAL**

- PO 83 OLD AGE IN ADULT CONGENITAL HEART DISEASE: A CONTEMPORARY REALITY  
PO 243 IS NON-VITAMIN K ORAL ANTICOAGULANTS SAFE IN ADULT CONGENITAL HEART DISEASE

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->  
20. CONGENITAL HEART DISEASE AND PEDIATRIC CARDIOLOGY -> 20.7 PEDIATRIC CARDIOLOGY**

- CO 137 FOLLOW-UP OF CHILDREN WITH BRUGADA SYNDROME: EXPERIENCE FROM A TERTIARY PAEDIATRIC REFERRAL CENTRE

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->  
21. PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE -> 21.2  
PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE - EPIDEMIOLOGY,  
PROGNOSIS, OUTCOME**

- PO 64 DIASTOLIC DYSFUNCTION IN PRECAPILLARY PULMONARY HYPERTENSION - LOOKING LEFT TO SEE RIGHT  
PO 65 WHAT ARE THE NEWS IN PULMONARY EMBOLISM RISK STRATIFICATION?  
PO 160 ECHOCARDIOGRAPHIC DATA IN ACUTE PULMONARY EMBOLISM - WHAT IS THE PROGNOSTIC VALUE IN THE REAL WORLD?  
CO 17 COMPERA SCORE REVISED: BETTER RISK ESTIMATION TO BETTER TAILOR THERAPEUTICS IN PRECAPILLARY HYPERTENSION.  
CO 19 PULMONARY HYPERTENSION IN CONNECTIVE TISSUE DISEASES WITH OVERT OR FEATURES OF VENOUS/CAPILLARIES INVOLVEMENT: CLINICAL IMPLICATIONS AND PROGNOSTIC IMPACT OF THIS PHENOTYPE.  
CO 136 RISK STRATIFICATION IN PULMONARY ARTERIAL HYPERTENSION: DO OUR PATIENTS BENEFIT FROM A 4-STRATA MODEL?  
CO 138 THORS SCORE, A BETTER PREDICTOR OF IN-HOSPITAL AND LONG-TERM MORTALITY AFTER ACUTE PULMONARY EMBOLISM?

**F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->  
21. PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE -> 21.3 PULMONARY  
CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE - DIAGNOSTIC METHODS**

- PO 157 ELECTROCARDIOGRAPHIC SCORE IN PREDICTING DIAGNOSIS AND SEVERITY OF PULMONARY EMBOLISM  
PO 158 COMPARISON OF DIFFERENT DIAGNOSTIC MODELS PERFORMANCE IN PATIENTS WITH COVID-19 AND PULMONARY EMBOLISM

- PO 159 AGE-DEPENDENCE PERFORMANCE OF DIAGNOSTIC PREDICTION RULES FOR PULMONARY EMBOLISM  
 CO 18 MULTIDIMENSIONAL CT APPROACH TO PREDICT HEMODYNAMICS IN PULMONARY HYPERTENSION

## **F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->**

### **21. PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE ->**

#### **21.4 PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE - TREATMENT**

- PO 63 REDUCING THE RISK IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION - FROM GUIDELINES TO PRACTICE  
 CO 16 ACUTE PULMONARY EMBOLISM CATHETER-DIRECTED THERAPY: FIRST RESULTS OF A MULTIPARAMETRIC FOLLOW-UP PROTOCOL  
 CO 20 RIGHT HEART REMODELING AFTER BALLOON PULMONARY ANGIOPLASTY IN PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION  
 CO 139 ACUTE PULMONARY EMBOLISM CATHETER-DIRECTED THERAPY: A SAFETY AND FEASIBILITY ANALYSIS

## **F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->**

### **21. PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE ->**

#### **21.6 PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE - CLINICAL**

- PO 156 PULMONARY THROMBOEMBOLISM: IS B-TYPE NATRIURETIC PEPTIDE AN EARLIER RISK MARKER?

## **G. AORTIC DISEASE, PERIPHERAL VASCULAR DISEASE, STROKE -> 22. AORTIC DISEASE ->**

### **22.4 AORTIC DISEASE - TREATMENT**

- PO 239 EARLY AORTIC VALVE REPLACEMENT IN ASYMPTOMATIC SEVERE AORTIC STENOSIS WITH PRESERVED EJECTION FRACTION  
 CO 34 EARLY AORTIC VALVE REPLACEMENT VERSUS CONSERVATIVE MANAGEMENT IN ASYMPTOMATIC SEVERE AORTIC STENOSIS

## **H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 25. INTERVENTIONAL**

### **CARDIOLOGY -> 25.1 INVASIVE IMAGING AND FUNCTIONAL ASSESSMENT**

- PO 24 COULD CMV VIREMIA HAVE AN IMPACT ON HEART TRANSPLANT PATIENTS' HEMODYNAMICS?  
 CO 45 ISCHEMIC HEART DISEASE: LOOKING BEYOND CORONARY STENOSIS

## **H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 25. INTERVENTIONAL**

### **CARDIOLOGY -> 25.2 CORONARY INTERVENTION**

- PO 112 RESIDUAL SYNTAX SCORE IN TAVR PATIENTS  
 PO 114 RADIATION IN THE CATH LAB: ARE PATIENTS REALLY SAFE?  
 PO 115 CONTRAST-INDUCED NEPHROPATHY FOLLOWING PCI: CAN WE CALCULATE A SAFE CONTRAST VOLUME?  
 PO 231 LEFT MAIN ARTERY LESIONS- THE ROLE OF IVUS AND CORONARY PHYSIOLOGY  
 PO 232 PERCUTANEOUS CORONARY INTERVENTION IN ELDERLY PATIENTS WITH CHRONIC KIDNEY DISEASE AND NON-ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME - IS IT WORTH IT?  
 PO 233 PCI OF CHRONIC TOTAL OCCLUSIONS: WHAT IS THE CLINICAL BENEFIT AND IMPACT ON QUALITY OF LIFE?  
 PO 234 PCI OF LEFT MAIN CORONARY ARTERY: REAL LIFE VS CLINICAL TRIALS OUTCOME RESULTS  
 PO 235 STENT STRATEGIES IN DISTAL LEFT MAIN LESIONS: THE SIMPLER, THE BETTER?  
 CO 35 META-ANALYSIS COMPARING OUTCOMES IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE IMPLANTATION WITH VERSUS WITHOUT PERCUTANEOUS CORONARY INTERVENTION  
 CO 41 A DECADE OF EXPERIENCE WITH ROTATIONAL ATERECTOMY: A SINGLE-CENTRE STUDY

## H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 25. INTERVENTIONAL CARDIOLOGY -> 25.3 NON-CORONARY CARDIAC INTERVENTION

- PO 113 SMALL-BORE ASPIRATION THROMBECTOMY VERSUS CATHETER-DIRECTED THROMBOLYSIS IN INTERMEDIATE-HIGH RISK ACUTE PULMONARY EMBOLISM
- PO 152 PERMANENT PACEMAKER IMPLANTATION AFTER ALCOHOLIC SEPTAL ABLATION: LONG-TERM OUTCOMES
- PO 153 LEFT ATRIAL APPENDAGE OCCLUSION IN PATIENTS WITH CHRONIC KIDNEY DISEASE OR CANCER: AN INTELLIGENT CHOICE?
- PO 154 LEFT ATRIAL APPENDAGE OCCLUSION IS AN EFFECTIVE AND SAFE STRATEGY FOR LONG TERM PREVENTION OF STROKE OR SYSTEMIC EMBOLISM
- PO 191 IMPACT OF THE USE OF CUSP OVERLAP PROJECTION TECHNIQUE IN THE INCIDENCE OF POST-TAVR PERMANENT PACEMAKER IMPLANTATION WITH SELF-EXPANDING VALVES
- PO 192 PREDICTORS OF FUNCTIONAL RECOVERY AFTER PERCUTANEOUS AORTIC VALVE IMPLANTATION - DATA FROM 459 CASES
- PO 193 BLEEDING AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION - WHAT ARE THE OUTCOMES AND HOW CAN WE PREDICT IT
- PO 194 IS ILIOFEMORAL CALCIUM VOLUME ASSOCIATED WITH VASCULAR AND BLEEDING COMPLICATIONS AFTER TAVI?
- PO 236 TRANS-SUBCLAVIAN TRANSCATHETER AORTIC VALVE IMPLANTATION: THE SECOND-LINE ACCESS
- PO 237 PERCUTANEOUS TRICUSPID VALVE INTERVENTION - EARLY EXPERIENCE IN A SINGLE CENTRE
- PO 238 CLINICAL OUTCOMES OF TRANSCATHETER AORTIC VALVE IMPLANTATION IN YOUNGER PATIENTS
- CO 31 VALVE-IN-VALVE TAVI FOR FAILING SURGICAL AORTIC BIOPROSTHETIC VALVES: A SINGLE-CENTRE EXPERIENCE
- CO 33 VASCULAR CLOSURE DEVICE IN TAVI WITH A DEDICATED ENDOVASCULAR PLUG-BASED DEVICE. EXPERIENCE FROM A HIGH-VOLUME TERTIARY CENTER
- CO 43 PERCUTANEOUS LEFT ATRIAL APPENDAGE CLOSURE: A SINGLE CENTER EXPERIENCE
- CO 101 PERCUTANEOUS BALLOON MITRAL VALVULOPLASTY FOR MITRAL STENOSIS PATIENTS: AN OLD BUT RELIABLE WEAPON
- CO 102 PREDICTORS OF FUNCTIONAL RECOVERY AFTER MITRAL TRANSCATHETER-EDGE-TO-EDGE REPAIR
- CO 103 REFINING PATIENT SELECTION TO PERCUTANEOUS MITRAL VALVE REPAIR IN SECONDARY MITRAL REGURGITATION
- CO 104 IMPACT OF RESIDUAL SIGNIFICANT MITRAL REGURGITATION IN TAVR PATIENTS

## H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 25. INTERVENTIONAL CARDIOLOGY -> 25.4 INTERVENTIONAL CARDIOLOGY - OTHER

- PO 111 BALLOON PULMONARY ANGIOPLASTY IN CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION: WHO BENEFITS THE MOST?
- PO 151 PERCUTANEOUS PATENT FORAMEN OVALE CLOSURE: 18 YEARS' EXPERIENCE IN A TERTIARY CENTRE
- PO 155 IS REAL WORLD PATENT FORAMEN OVALE CLOSURE A SAFE AND EFFECTIVE STRATEGY?
- PO 195 CONTEMPORARY MANAGEMENT AND OUTCOMES OF PATIENTS WITH VASCULAR COMPLICATIONS DURING TRANSFEMORAL TAVI.
- PO 240 BIVALVE: PROCEDURAL AND MID-TERM RESULTS IN PATIENTS WITH AORTIC STENOSIS TREATED WITH IMPLANTATION OF 2 (IN-SERIES) PROSTHESES IN A SINGLE PROCEDURE
- CO 32 TRANSCATHETER AORTIC VALVE DESIGN AND MORTALITY: TRUTH OR REALITY?
- CO 42 RESIDUAL SHUNT AFTER PATENT FORAMEN OVALE CLOSURE: PREDICTORS' AND ITS IMPACT ON LONG-TERM OUTCOMES
- CO 44 3D PRINTING FOR LEFT ATRIAL APPENDAGE CLOSURE: A META-ANALYSIS OF COHORT STUDIES
- CO 105 CAROTID ANGIOPLASTY STENTING VERSUS ENDARTERECTOMY VERSUS BEST MEDICAL TREATMENT - WHAT IS THE BEST STRATEGY FOR THE TREATMENT OF CAROTID STENOSIS?

## H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 26. CARDIOVASCULAR SURGERY -> 26.2 CARDIOVASCULAR SURGERY - VALVES

- PO 23 MORTALITY PREDICTORS IN INFECTIVE ENDOCARDITIS PATIENTS SUBMITTED TO SURGERY - WHAT CAN BE IMPROVED?

**H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 26. CARDIOVASCULAR SURGERY -> 26.8 CARDIOVASCULAR SURGERY - TRANSPLANTATION**

PO 22 QUILTY EFFECT AND ITS UNCERTAIN REPERCUSSION IN HEART TRANSPLANTED PATIENTS

**H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 26. CARDIOVASCULAR SURGERY -> 26.11 CARDIOVASCULAR SURGERY - OTHER**

PO 21 POSTSTERNOTOMY MEDIASTITIS - OUR 10 YEAR EXPERIENCE WITH OMENTUM FLAP SURGERY

**I. HYPERTENSION -> 27. HYPERTENSION -> 27.2 HYPERTENSION - EPIDEMIOLOGY, PROGNOSIS, OUTCOME**

PO 103 HIGH SALT INTAKE IS A RISK FACTOR FOR KIDNEY FAILURE/MICROALBUMINURIA IN HYPERTENSIVE PATIENTS

PO 105 DOES IT MAKE SENSE TO USE QUESTIONNAIRES TO ASSESS THE CARDIOVASCULAR RISK OF HYPERTENSIVE PATIENTS?

**I. HYPERTENSION -> 27. HYPERTENSION -> 27.4 HYPERTENSION - TREATMENT**

CO 125 EFFECTS OF HOME-BASED ISOMETRIC HANDGRIP TRAINING IN OLDER ADULTS WITH HIGH BLOOD PRESSURE

**I. HYPERTENSION -> 27. HYPERTENSION -> 27.5 HYPERTENSION - PREVENTION**

CO 124 SYNERGISM OF TWO ACE GENE VARIANTS IN THE ONSET OF HYPERTENSION IN A PORTUGUESE POPULATION

**J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.1 RISK FACTORS AND PREVENTION - EPIDEMIOLOGY**

CO 24 PROGNOSTIC ROLE OF ADDING A GENETIC RISK SCORE TO THE NEW EUROPEAN SCORE2 IN CARDIOVASCULAR EVENTS PREDICTION, IN A MODERATE-RISK REGION

**J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.2 RISK FACTORS AND PREVENTION - CARDIOVASCULAR RISK ASSESSMENT**

PO 141 CARDIOVASCULAR OUTCOMES ACCORDING TO RISK CATEGORY: RESULTS OF A RETROSPECTIVE DATABASE STUDY

PO 142 DO ATHEROSCLEROTIC EVENTS CHANGE LIPID LOWERING THERAPY USE IN CLINICAL PRACTICE?THE ANSWER WITH RWE

CO 21 POTENTIAL IMPACT OF REPLACING SCORE WITH SCORE-2 ON RISK CLASSIFICATION AND STATIN ELIGIBILITY - A CORONARY CALCIUM SCORE CORRELATION STUDY

CO 22 THE EVALUATION OF THE EUROPEAN SCORE2 IN A PORTUGUESE POPULATION

CO 25 A NEW SCORE MODEL FOR MORTALITY PREDICTION IN TREADMILL TEST

**J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.3 SECONDARY PREVENTION**

CO 74 + CORAÇÃO + VIDA: MAIOR ARTICULAÇÃO E VIGILÂNCIA DO UTENTE COM PATOLOGIA CARDIOVASCULAR E SUAS FAMÍLIAS

**J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.4 LIPIDS**

PO 101 FAMILIAL HYPERCHOLESTEROLEMIA IN ACUTE CORONARY SYNDROME PATIENTS: UNDERDIAGNOSIS IN FEMALE AND IN YOUNG PATIENTS

PO 102 LDL-CHOLESTEROL LEVELS AFTER ACUTE CORONARY SYNDROME: 24-MONTHS VARIATIONS AND IMPACT ON OUTCOMES

PO 104 REAL-WORLD ASSESSMENT OF IPCSK9 TREATMENT ADHERENCE, EFFECTIVENESS, AND TOLERABILITY: A PRELIMINARY ANALYSIS

## **J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.6 OBESITY**

CO 123 IS THE OBESITY PARADOX LEADING TO A LESS STRINGENT SECONDARY PREVENTION STRATEGY IN PATIENTS WHO HAVE SUSTAINED AN ACUTE CORONARY SYNDROME?

## **J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.7 DIABETES AND THE HEART**

PO 143 URIC ACID AS A RISK FACTOR FOR CARDIOVASCULAR DISEASE AND MORTALITY

## **J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.12 PHYSICAL INACTIVITY AND EXERCISE**

PO 185 TREADMILL TESTING AND PROGNOSIS: ARE WE LOOKING AT THE RIGHT THINGS?

## **J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.14 RISK FACTORS AND PREVENTION - OTHER**

PO 144 IMPORTANCE OF A GENETIC SCORE IN ASSESSING THE RISK OF ARTERIAL STIFFNESS

PO 145 ANTITHROMBOTIC STRATEGIES AFTER LAA OCCLUSION - IS THERE A WINNING STRATEGY?

CO 23 PROGNOSTIC IMPACT OF ADDING CORONARY CALCIUM SCORE TO EUROPEAN SCORE2 IN AN ASYMPTOMATIC PORTUGUESE POPULATION

## **J. PREVENTIVE CARDIOLOGY -> 29. REHABILITATION AND SPORTS CARDIOLOGY -> 29.1 EXERCISE TESTING**

PO 181 EXERCISE TRAINING IMPROVES CARDIORESPIRATORY FITNESS IN HEART FAILURE PATIENTS: A LOOK BEYOND PEAK OXYGEN CONSUMPTION

PO 182 VALUE OF CARDIOPULMONARY EXERCISE TEST SUBMAXIMAL PARAMETERS IN THE ASSESSMENT OF AORTIC STENOSIS PATIENTS

## **J. PREVENTIVE CARDIOLOGY -> 29. REHABILITATION AND SPORTS CARDIOLOGY -> 29.2 CARDIOVASCULAR REHABILITATION**

PO 131 OUTCOMES OF PATIENTS ENROLLED IN A PHASE 2 CARDIAC REHABILITATION PROGRAM ACCORDING TO ACUTE CORONARY SYNDROME

PO 132 CARDIAC REHABILITATION AFTER ELECTIVE HEART SURGERY: A VALVULAR SURGERY FOCUSED COMPARISON TO CORONARY ARTERY BYPASS GRAFTING

PO 133 THE RISE OF THE DIGITAL ERA IN CARDIAC REHABILITATION: CAN IT KEEP UP WITH THE PRESENTIAL MODEL?

PO 134 SHORTER CARDIAC REHABILITATION PROGRAMS: TAKING TIME IS TAKING EFFECTIVENESS?

PO 135 CARDIAC REHABILITATION PROGRAMS: DOES SHORTER COURSE TRANSLATE INTO LESS EXERCISE CAPACITY?

PO 183 CARDIAC OPTIMAL POINT: IDENTIFYING HIGH RISK PATIENTS FOR AN OPTIMAL APPROACH

PO 184 VERY ACUTE BENEFITS ON PHYSICAL PERFORMANCE IN ELDERLY PATIENTS WHO UNDERGONE TAVI

CO 121 CARDIAC REHABILITATION AND MUSCLE EFFICIENCY IMPROVEMENT IN HEART FAILURE PATIENTS

CO 122 IMPACT OF CARDIAC REHABILITATION ON INFLAMMATION IN PATIENTS WITH ISCHAEMIC CARDIOMYOPATHY

**J. PREVENTIVE CARDIOLOGY -> 29. REHABILITATION AND SPORTS CARDIOLOGY ->  
29.4 REHABILITATION AND SPORTS CARDIOLOGY - OTHER**

PO 74 EXERCISE TRAINING IN CARDIAC REHABILITATION AND CHANGES IN SELF-REPORTED HEALTH RELATED QUALITY OF LIFE

**K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE  
IN SPECIAL POPULATIONS -> 30.2 CARDIOVASCULAR DISEASE IN WOMEN**

PO 15 SEX DISPARITIES IN LIPID-LOWERING THERAPY AND DYSLIPIDEMIC CONTROL IN A CORONARY REHABILITATION PROGRAM

**K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE  
IN SPECIAL POPULATIONS -> 30.3 CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS:  
PEDIATRIC CARDIOLOGY**

PO 227 MYOCARDITIS AND PERICARDITIS FOLLOWING COVID-19 VACCINATION IN ADOLESCENTS

CO 79 CARDIOPULMONARY EXERCISE TESTING IN FONTAN PATIENTS: UNMASKING THE SECRET OF "SUPER-FONTANS"

**K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE  
IN SPECIAL POPULATIONS -> 30.6 CARDIO-ONCOLOGY**

PO 241 PREDICTORS OF CARDIOTOXICITY IN PATIENTS WITH BREAST CANCER: A PROSPECTIVE STUDY

CO 76 PREVALENCE OF RV DYSFUNCTION IN PATIENTS UNDER CARDIOTOXIC CHEMOTHERAPY: A PRELIMINARY ANALYSIS

CO 77 CARDIOTOXICITY IN BREAST CANCER PATIENTS - RISK FACTORS AND ROLE OF CARDIOPROTECTIVE DRUGS

**K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE  
IN SPECIAL POPULATIONS -> 30.7 PREGNANCY AND CARDIOVASCULAR DISEASE**

CO 73 VASCULAR REMODELLING DURING PREGNANCY AND POSTPARTUM

CO 78 THE IMPACT OF COMORBIDITIES IN CARDIAC REMODELLING AND REVERSE REMODELLING INDUCED BY PREGNANCY

**K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE  
IN SPECIAL POPULATIONS -> 30.9 RENAL FAILURE AND CARDIOVASCULAR DISEASE**

PO 11 PERI-PROCEDURAL, 30-DAY AND 1 YEAR-OUTCOMES IN CHRONIC DIALYSIS PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE IMPLANTATION

PO 14 PREVALENCE AND MANAGEMENT OF CARDIOVASCULAR DISEASE IN PATIENTS WITH PRIOR RENAL TRANSPLANTATION

PO 246 CAD IN KIDNEY TRANSPLANT RECIPIENTS: A REAL-WORLD ASSESSMENT PRE-ISCHEMIA-CKD

**K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE  
IN SPECIAL POPULATIONS -> 30.12 AUTOIMMUNE/CHRONIC INFLAMMATORY DISORDERS  
AND HEART DISEASE**

PO 12 SCREENING PULMONARY HYPERTENSION IN SYSTEMIC SCLEROSIS USING CARDIOPULMONARY EXERCISE TEST

**K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE  
IN SPECIAL POPULATIONS -> 30.14 CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS - OTHER**

PO 13 ACUTE CORONARY SYNDROMES IN YOUNG PEOPLE: APPLICABILITY OF THE GRACE AND CRUSADE SCORES

PO 226 PREDICTORS OF DYSRHYTHMIAS IN COVID-19 INTENSIVE CARE PATIENTS AND IMPACT ON IN-HOSPITAL MORTALITY

- PO 228 THROMBOEMBOLIC EVENTS IN THE FOLLOW UP OF COVID-19 PATIENTS
- PO 229 COMPARISON OF 5 ACUTE PULMONARY EMBOLISM MORTALITY RISK SCORES IN PATIENTS WITH COVID-19
- PO 230 IS STANDARD CARDIAC EVALUATION ENOUGH FOR COVID-19 PATIENTS WITH SEVERE DISEASE?
- PO 245 THE VALUE OF ADMISSION NT-PROBNP IN PROGNOSIS OF PATIENTS HOSPITALIZED WITH COVID-19 AND WITHOUT HISTORY OF HEART FAILURE.

#### **M. CARDIOVASCULAR NURSING -> 32. CARDIOVASCULAR NURSING -> 32.1 ACUTE NURSING CARE**

- PO 71 THE NURSE-FAMILY INTERACTION OF THE CRITICALLY ILL PERSON IN A CARDIAC INTENSIVE CARE UNIT

#### **M. CARDIOVASCULAR NURSING -> 32. CARDIOVASCULAR NURSING -> 32.2 CHRONIC NURSING CARE**

- CO 75 IMPACTO DA INTERVENÇÃO DO ENFERMEIRO DE REABILITAÇÃO NA REDUÇÃO DOS REINTERNAMENTOS POR INSUFICIÊNCIA CARDÍACA AOS 30 DIAS

#### **M. CARDIOVASCULAR NURSING -> 32. CARDIOVASCULAR NURSING -> 32.3 CARDIOVASCULAR NURSING - OTHER**

- PO 72 FUNCTIONAL CAPACITY ASSESSMENT OF ISCHEMIC PATIENTS AFTER ACUTE EVENT USING THE 6MWT
- CO 71 PERCEPTION OF NOISE IN A CICU: IMPLICATIONS ON THE WELL-BEING OF PERSON IN CRITICAL SITUATION

#### **N. E-CARDIOLOGY / DIGITAL HEALTH, PUBLIC HEALTH, HEALTH ECONOMICS, RESEARCH METHODOLOGY -> 33. E-CARDIOLOGY / DIGITAL HEALTH -> 33.1 IMAGE PROCESSING AND IMAGING STANDARDS**

- CO 85 APPLICATION OF ARTIFICIAL INTELLIGENCE IN CORONARY CT ANGIOGRAPHY: A POTENTIAL GATEKEEPER STRATEGY?

#### **N. E-CARDIOLOGY / DIGITAL HEALTH, PUBLIC HEALTH, HEALTH ECONOMICS, RESEARCH METHODOLOGY -> 33. E-CARDIOLOGY / DIGITAL HEALTH -> 33.4 DIGITAL HEALTH**

- CO 95 DEVELOPMENT OF DEEP LEARNING SEGMENTATION MODELS FOR CORONARY X-RAY ANGIOGRAPHY: PERFORMANCE ASSESSMENT BY NEW CLINICAL CRITERIA SCORE AND COMPARISON WITH HUMAN PERFORMANCE

#### **O. BASIC SCIENCE -> 36. BASIC SCIENCE -> 36.2 BASIC SCIENCE - CARDIAC BIOLOGY AND PHYSIOLOGY**

- PO 53 IMPACT OF EXERCISE TRAINING AND CARVEDILOL ON CARDIOVASCULAR PARAMETERS IN DOXORUBICIN TREATED RATS
- PO 54 CUMULATIVE DOXORUBICIN DOSAGE IS A TRIGGERING FACTOR FOR COGNITIVE AND PHYSIOLOGICAL DYSFUNCTION?
- CO 82 TRANSCRIPTION FACTOR 21 AND PROGNOSIS IN A CAD POPULATION

#### **O. BASIC SCIENCE -> 36. BASIC SCIENCE -> 36.3 BASIC SCIENCE - CARDIAC DISEASES**

- PO 52 ZNF 259C>G VARIANT RS964184 IS ASSOCIATED WITH CORONARY ARTERY DISEASE AND DYSLIPIDEMIA IN THE YOUNGER POPULATION
- CO 81 HISTOLOGY-VERIFIED MYOCARDIAL FIBROSIS IN SEVERE AS PATIENTS: PREVALENCE AND CORRELATION WITH NON-INVASIVE LV MYOCARDIAL TISSUE ASSESSMENT
- CO 84 THERAPEUTIC EFFECT OF UROCORTIN-2 IN HEART FAILURE WITH PRESERVED EJECTION FRACTION

**O. BASIC SCIENCE -> 36. BASIC SCIENCE -> 36.5 BASIC SCIENCE - VASCULAR DISEASES**

PO 51 THERAPEUTIC EFFECTS OF NEBULIZATION- BASED DELIVERY OF ANTI-MIR-146A IN EXPERIMENTAL PULMONARY ARTERIAL HYPERTENSION

PO 55 PULMONARY EMBOLISM - PLATELET INDICES' IN PATIENTS WITH OR WITHOUT RIGHT VENTRICULAR DILATATION

**O. BASIC SCIENCE -> 36. BASIC SCIENCE -> 36.6 BASIC SCIENCE - OTHER**

CO 83 PLASMA LIPIDOMICS IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION

**P. OTHER -> 37. MISCELLANEA**

PO 31 PREDICTING THE LONG-TERM OUTCOME OF PATIENTS ADMITTED WITH ACUTE HEART FAILURE TO THE EMERGENCY DEPARTMENT USING RENAL MARKERS